News
Read our latest SpOTLight newsletter for a digest of OTL news:
-
SPOTLIGHT June 2025 - Annual Report FY2024
This edition brings you our Annual Report for Fiscal Year 2023-2024: "Bridging to Impact"
June 11, 2025
Read additional news about OTL, our licensees, and Stanford technologies:
-
July 09, 2025
-
SPOTLIGHT June 2025 - Annual Report FY2024
This edition brings you our Annual Report for Fiscal Year 2023-2024: "Bridging to Impact"
June 11, 2025
-
A game-changing way to treat stroke
Profile of HIT Fund Awardee: Milli-Spinner
June 04, 2025
-
Hitting Its Stride
Teams Raise Capital, Find Playbook for Commercialization
June 01, 2025
-
May 30, 2025
-
Stanford HIT Fund Opens 2025 Call for Applications
Applications are due June 22, 2025
May 19, 2025
-
HIT Fund: Helping Stanford innovators commercialize their research
HIT Fund awardees share their perspectives
May 12, 2025
-
Stanford Licensee Abeona Therapeutics receives U.S. FDA Approval for ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
ZEVASKYN fills a critical need for people living with RDEB, a debilitating dermatological condition with no cure.
April 29, 2025
-
New tool lets scientists observe genome dynamics in real time
A technique to see DNA as it moves in living cells could offer novel fundamental insights into biology.
April 25, 2025
-
‘Engineering is fundamentally about solving problems’
Profile of HIT Fund Awardee: Eric Appel, Injectable Hydrogels
April 17, 2025
-
Stanford Licensee Epicrispr Biotechnologies Announces FDA Clearance of IND Application for EPI-321, A First-in-Class Epigenetic Therapy for FSHD
Epic Bio is a biotechnology company focused on developing curative therapies.
April 03, 2025
-
HIT Fund Lab to Market Seminar Series: Open Source Considerations
Isaac Fine, Partner, KPPB, shares insights with the Stanford community
February 20, 2025
-
January 24, 2025
-
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor
Vera Therapeutics has announced an exclusive license agreement with Stanford University.
January 13, 2025
-
Stanford Researcher Helen Blau awarded the National Medal of Science
Stem cell biologist Helen Blau was recognized for her work on cellular plasticity and aging.
January 12, 2025
-
Stanford Licensee Synthekine Presents Positive Initial Results from Phase 1 Clinical Trial of CD19 CAR-T (SYNCAR-001) and Orthogonal IL-2 (STK-009) Combination Therapy for Treatment of Hematologic Malignancies at ASH 2024 Annual Meeting
Synthekine Inc., which was founded on tech licensed from K. Christopher Garcia’s Stanford lab, today announced positive initial results from a first-in-human Phase 1 study.
December 09, 2024
-
BridgeBio's Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
Acoramidis is based on a Stanford technology licensed by Eidos Therapeutics, which BridgeBio acquired in 2021.
November 22, 2024
-
Stanford Licensee Valora Therapeutics Raises $30 Million Seed Financing from Top Investors to Transform Immunotherapy with a Novel Glyco-immune Checkpoint Platform
Valora, a biotech company pioneering a novel approach to immunotherapy, today announced the successful closing of its seed funding round.
November 20, 2024
-
SPOTLIGHT October 2024
Featured Story: A Revolution in Composites: Professor Stephen Tsai's Vision for a Lighter Future
October 24, 2024
-
October 22, 2024
